Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 plus paclitaxel versus chemotherapy for second-line small cell lung cancer
ChiCTR2400091077Phase 3Recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Oct 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of pumitamig, paclitaxel and topotecan in small cell lung cancer (SCLC) (2 arms), sponsored by Jilin Provincial Cancer Hospital. Primary endpoint: overall survival. Started Oct 2024; status: recruiting.
02
Drugs
pumitamigpaclitaxeltopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400091077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091077.